AstraZeneca: leukaemia drug meets primary endpoint in trial

(CercleFinance.com) - AstraZeneca said on Thursday that its Calquence drug successfully met the primary endpoint in a late-stage trial in patients with previously-untreated chronic lymphocytic leukaemia.


Results of the phase III study found that Calquence, in combination with Roche's obinutuzumab, demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival when compared with chemotherapy-based treatment.

The trial also met a key secondary endpoint, showing Calquence monotherapy achieved a statistically-significant and clinically-meaningful improvement in progression-free survival compared to the chemotherapy-based treatment.

Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma.

The shares of AstraZeneca are currently up 1.3% in London, compared to a 0.4% rise in the FTSE 100 index.

Copyright (c) 2019 CercleFinance.com. All rights reserved.